Abstract: The disclosure provides pharmaceutical compositions comprising an anti-PD-1 antibody or an anti-PD-L1 antibody. In some aspects, the pharmaceutical compositions are formulated for subcutaneous delivery. In some aspects, the pharmaceutical compositions further comprise an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering a pharmaceutical composition comprising an anti-PD-1 antibody or an anti-PD-L1 antibody.

Abstract: The disclosure provides pharmaceutical compositions comprising an antibody and at least two antioxidants. In some aspects, pharmaceutical composition is formulated for subcutaneous delivery. In some aspects, the pharmaceutical composition further comprises an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering the pharmaceutical composition.

Abstract: The disclosure provides pharmaceutical compositions comprising an anti-PD-1 antibody or an anti-PD-L1 antibody. In some aspects, the pharmaceutical compositions are formulated for subcutaneous delivery. In some aspects, the pharmaceutical compositions further comprise an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering a pharmaceutical composition comprising an anti-PD-1 antibody or an anti-PD-L1 antibody.

Abstract: The disclosure provides pharmaceutical compositions comprising an anti-PD-1 antibody or an anti-PD-L1 antibody. In some aspects, the pharmaceutical compositions are formulated for subcutaneous delivery. In some aspects, the pharmaceutical compositions further comprise an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering a pharmaceutical composition comprising an anti-PD-1 antibody or an anti-PD-LI antibody.

Abstract: This technology generally relates to techniques for validating freeform entries in web forms, such that providers of a service can receive an optimal amount of information from potential users of that service in the initial correspondence. The techniques may include receiving a query from a consumer and analyzing the query using natural language parsing of a machine learning model, such as a large language model. The machine learning model may generate a series of prompts related to the content of the query. The user may provide additional information based on the series of prompts. The techniques may further include analyzing the additional information to determine if the prompts were addressed. If the prompts were addressed, the techniques may include outputting a complete message to the user.

Abstract: The disclosure provides pharmaceutical compositions comprising an antibody and at least two antioxidants. In some aspects, pharmaceutical composition is formulated for subcutaneous delivery. In some aspects, the pharmaceutical composition further comprises an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering the pharmaceutical composition.

Abstract: This technology generally relates to techniques for validating freeform entries in web forms, such that providers of a service can receive an optimal amount of information from potential users of that service in the initial correspondence. The techniques may include receiving a query from a consumer and analyzing the query using natural language parsing of a machine learning model, such as a large language model. The machine learning model may generate a series of prompts related to the content of the query. The user may provide additional information based on the series of prompts. The techniques may further include analyzing the additional information to determine if the prompts were addressed. If the prompts were addressed, the techniques may include outputting a complete message to the user.

Abstract: The disclosure provides pharmaceutical compositions comprising an anti-PD-1 antibody or an anti-PD-L1 antibody. In some aspects, the pharmaceutical compositions are formulated for subcutaneous delivery. In some aspects, the pharmaceutical compositions further comprise an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering a pharmaceutical composition comprising an anti-PD-1 antibody or an anti-PD-L1 antibody.

Abstract: The disclosure provides pharmaceutical compositions comprising an anti-PD-1 antibody or an anti-PD-L1 antibody. In some aspects, the pharmaceutical compositions are formulated for subcutaneous delivery. In some aspects, the pharmaceutical compositions further comprise an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering a pharmaceutical composition comprising an anti-PD-1 antibody or an anti-PD-L1 antibody.

Abstract: The disclosure provides pharmaceutical compositions comprising an anti-PD-1 antibody or an anti-PD-L1 antibody. In some aspects, the pharmaceutical compositions are formulated for subcutaneous delivery. In some aspects, the pharmaceutical compositions further comprise an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering a pharmaceutical composition comprising an anti-PD-1 antibody or an anti-PD-L1 antibody.

Abstract: The disclosure provides pharmaceutical compositions comprising an antibody and at least two antioxidants. In some aspects, pharmaceutical composition is formulated for subcutaneous delivery. In some aspects, the pharmaceutical composition further comprises an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering the pharmaceutical composition.

Abstract: A formation method is provided. During this formation method, a metallic substrate is provided. A coating is deposited onto the metallic substrate using a suspension plasma spray process. The coating is formed from or otherwise includes copper oxide.

Abstract: Disclosed is an approach to implement an architecture and methodology that allows rapid access to provisioned software without requiring the entirety of the software distribution to be transferred to the target system in an upfront manner. Instead, a multi-tier architecture is used that allows the software to be provisioned and accessed with efficient access and reads of distribution materials from one or more remote storage locations.

Abstract: Disclosed is an approach to implement an architecture and methodology that allows rapid access to provisioned software without requiring the entirety of the software distribution to be transferred to the target system in an upfront manner. Instead, a multi-tier architecture is used that allows the software to be provisioned and accessed with efficient access and reads of distribution materials from one or more remote storage locations.

Abstract: The disclosure provides pharmaceutical compositions comprising an anti-PD-1 antibody or an anti-PD-L1 antibody. In some aspects, the pharmaceutical compositions are formulated for subcutaneous delivery. In some aspects, the pharmaceutical compositions further comprise an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering a pharmaceutical composition comprising an anti-PD-1 antibody or an anti-PD-L1 antibody.

Abstract: The disclosure provides pharmaceutical compositions comprising an antibody and at least two antioxidants. In some aspects, pharmaceutical composition is formulated for subcutaneous delivery. In some aspects, the pharmaceutical composition further comprises an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering the pharmaceutical composition.

Abstract: Techniques are provided for transitioning from a hierarchical file system to an object store. A request is received to change file metadata of a hierarchical file system. In response to the request: in-cache file metadata of the hierarchical file system is modified. The in-cache file metadata includes a directory structure of the hierarchical file system and file metadata of the hierarchical file system. Additionally, an in-store metadata journal entry is generated. The in-store metadata journal entry indicates an update to in-store file metadata. The in-store file metadata includes the directory structure of the hierarchical file system and file metadata of the hierarchical file system and is stored in an object store. The in-store metadata journal entry is stored in the object store. Furthermore, in-store file metadata and in-store metadata journal entry may be used to reconstruct the in-cache file metadata on another node.

Abstract: A method, computer program product, and computing system for determining, at the computing device, one or more dependencies associated with a plurality of managed objects and a plurality of backend objects. One or more backend notifications associated with one or more backend objects of the plurality of backend objects may be received. One or more managed objects of the plurality of managed objects associated with the one or more backend objects of the one or more backend notifications may be identified, based upon, at least in part, the one or more dependencies associated with the plurality of managed objects and the plurality of backend objects. The one or more identified managed objects of the plurality of managed objects may be updated based upon, at least in part, the one or more backend notifications.

Abstract: The present relates to a method for managing user service assignments in a cloud service environment, the method includes receiving a file that includes provisioning for at least one service, processing the file based at least in part on a plurality of attributes in the file, the each of the plurality of attributes associated with the at least one service, creating a service request based at least in part on the file, the service request comprising a plurality of service data attributes, creating an extensible markup language (XML) string based at least in part on the service request, invoking a provisioning agent programming interface (API), and provisioning a service to fulfill the service assignments.

Abstract: Techniques are provided for transitioning from a hierarchical file system to an object store. A request is received to change file metadata of a hierarchical file system. In response to the request: in-cache file metadata of the hierarchical file system is modified. The in-cache file metadata includes a directory structure of the hierarchical file system and file metadata of the hierarchical file system. Additionally, an in-store metadata journal entry is generated. The in-store metadata journal entry indicates an update to in-store file metadata. The in-store file metadata includes the directory structure of the hierarchical file system and file metadata of the hierarchical file system and is stored in an object store. The in-store metadata journal entry is stored in the object store. Furthermore, in-store file metadata and in-store metadata journal entry may be used to reconstruct the in-cache file metadata on another node.